Merck KGaA

MRK.F·Frankfurt·Healthcare
Compare
145.600.00 (0.00%)today
As of Oct 23, 8:10 AM CEST · May be delayed up to 15 min · EUR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close145.60
Open145.60
Day range—
52-week range100.65147.95
Off day high0.00%
Off 52-week high−1.59%
Volume75.00
Avg. volume (3M)488
Market cap63.30B
EPS (TTM)5.45
Forward P/E16.30
P/E ratio (TTM)26.72
Dividend yield1.55% (2.20)
Beta (5Y)0.79
Shares outstanding129.24M
Short interest—
Earnings dateNov 12, 2026
Analyst target154.21
Profit margin11.21%

Against its peers

Compare in full ›
MRK.F 1795.TW KNSA ZYDUSLIFE.NS 0QFP.IL SFZN.SW
Market cap 63.30B 45.96B 6.30B 1.13T 1.74T 3.19B
P/E (TTM) 26.7 12.1 81.6 25.2 7.3 18.6
Forward P/E 16.3 7.3 46.7 22.8 — 15.4
Price/book 2.1 1.9 9.6 4.2 0.8 3.2
Dividend yield 1.55% 1.49% — 0.09% 7.74% 0.55%
1-year change +27.22% −38.58% +107.53% +12.95% 0.00% −10.95%
Today 0.00% −1.99% +1.37% −0.49% 0.00% +0.21%

The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.

Latest news

All MRK.F news ›
MarketScreener·Positive

Silence Therapeutics to be Acquired by Merck KGaA for $20 Per ADS

Silence Therapeutics said Monday it has entered into a definitive agreement to be acquired by Merck KGaA in Darmstadt, Germany in an all-cash deal with an enterprise value of $1.1 billion and an... Biotechnology & Medical Research Silence…

MarketScreener·Negative

Merck KGaA : Jefferies reiterates its Neutral rating

Published on 10/19/2026 at 11:18 am EDT Merck: Operational resilience over the years, cannot be overlooked September 04, 2026 at 08:34 am EDT Merck KGaA: From 19th-century cocaine to tomorrow's AI chips Merck CEO on US Business, Life…

MarketScreener·Negative

Merck KGaA to Spend $1.3bn on Silence Therapeutics

Merck KGaA (-0.83%, at EUR143.10) announced that it has signed a definitive agreement to acquire British biotechnology company Silence Therapeutics, which specializes in developing therapies based on small interfering RNAs (siRNAs). The…

Seeking Alpha·Positive

Merck KGaA to buy Silence Therapeutics in all-cash deal

Merck KGaA to acquire Silence Therapeutics for $1.3B cash, a 130% premium, boosting siRNA pipeline and rare-disease focus. Merck KGaA (MKGAY) (MKGAF) has agreed to acquire Silence Therapeutics (SLN) in an all-cash deal with an enterprise…

From articles in the 4Search news index.

In the news

174mentions in 30 days
34with it in the headline
Positivesentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.